illumin director Paul Khawaja buys into a June cluster

What Khawaja bought, and why the filing matters

Paul Khawaja, a director at illumin Holdings Inc., bought shares on June 24, 2026, in a transaction valued at approximately EUR 22,359, according to the filing at ceo.ca. The trade was marked as a BUY, carried a score of 53 in our system, and was flagged as part of an insider cluster. That is the actual event. Everything else is interpretation, and the interpretation starts with the fact that this was not a lone nibble from a passive holder. It came after other director buying in the same name during June.

The company is a micro cap, with a market value of about EUR 36.35 million in our dossier. That matters because insider buying in small names tends to be more informative than the same euro amount would be in a large, liquid issuer. It also means the trade size deserves to be read in context. EUR 22,359 is not a boardroom wager on the future of the company. It is, however, enough to show up in a name where insiders can move around the tape more visibly than the market usually admits.

The signal score is middling for a reason

Our scoring gave the filing 53, which is not the sort of number that asks you to suspend disbelief. It is a workable signal, not a trumpet blast. The drivers are straightforward. Khawaja is an operating director, the trade sits inside a cluster of insider purchases, the filing value is around EUR 22,359, the position size is about 0.06% of the company’s market value, and illumin sits in the small-cap band where insider information has historically been least priced in. Each of those factors pushes the score in the same direction, but none of them is exotic. The trade is notable because the pieces line up, not because any single piece is dramatic.

That is the right way to read a filing like this. A director buy in a micro-cap media name can be meaningful without being heroic. The score does not say the stock is cheap, the business is turning, or the next quarter will surprise. It says the trade sits in a pattern our model has learned to respect more than a random one-off purchase. If you are weighing the name, the cluster math is the part to sit with. A single director buying can be noise. Multiple insiders buying in a short window is harder to dismiss.

illumin is still a micro-cap story first

illumin Holdings Inc. trades in the media sector and sits in our micro-cap bucket. That is not a cosmetic label. It tells you the market is thin enough for insider activity to matter, but also thin enough for fundamentals and liquidity to dominate the tape. The company’s market cap in our dossier is EUR 36.35 million, which is small even by Canadian small-cap standards. In names like this, insider filings often become one of the few public windows into board-level conviction, because the market itself does not always provide a clean read.

The company also held its annual meeting of shareholders on June 11, 2026, and all director nominees were elected, according to the voting-results release. That does not tell you much about the stock by itself, but it does tell you the board structure remained intact as the June insider activity unfolded. No company statement or analyst note in the recent disclosures specifically addressed the June 24 buy. So the filing stands on its own. That is often how these things arrive. No commentary, no color, just a director putting money into the name while the market is busy looking elsewhere.

The tape shows more than one buyer

The June 24 Khawaja filing does not sit alone. Public records also show director Bruce William Barker buying on June 17 at CAD 0.52 per share for 25,900 shares, and again on June 9 at CAD 0.57 per share for 28,700 shares, according to the insider-transaction records. Earlier Khawaja activity also appears in May 2026 filings. That is the cluster picture in plain English. Multiple director purchases, spread across June, with one director recurring. It is not a single burst of enthusiasm from one person. It is a pattern.

Our dossier marks the cluster as true, with 3 distinct insiders and 11 recent declarations. The recent list includes repeated June 24 entries for Khawaja, including BUY and OTHER designations in the filing trail, plus Barker’s June 17 BUY. For a reader, the important point is not the count for its own sake. It is that the company has had enough insider activity in a short window to make the June tape worth reading as a group rather than as isolated lines in a database. Clustered buying can be a sign that the board sees the same thing from different angles. It can also be a sign of routine accumulation. The filing set does not let you choose between those explanations with certainty, and anyone pretending otherwise is selling certainty they do not have.

The historical cohort data is weak, not flattering

Here is the part that keeps the whole exercise honest. Our cohort data for the Director · Micro bucket, which is the relevant role-and-size bucket for Khawaja’s trade, covers 8,949 observations. The 90-day win rate is 25.7 percent. The average 90-day return is -12.69 percent. The average 365-day return is -21.93 percent. That is historical cohort data, not a forecast, and not a promise about illumin specifically. But it is the right backdrop for a trade like this, because it tells you what this kind of filing has done in aggregate when the market has had time to digest it.

Those numbers are not flattering. They say that director buying in micro caps has, in our sample, been a poor standalone timing tool. The win rate is low, and the mean return is negative at both the 90-day and 365-day marks. If you are looking for a clean momentum story, this is not it. The correct conclusion is more modest. Insider buying can still matter, but the burden of proof is on the company to convert the filing into actual operating progress. Without that, the cohort history says the market has usually been right to stay skeptical. That is the read you want when the data is honest.

The fundamentals are thin, which is part of the problem

Our fundamental screen on illumin is not a clean bill of health. The dossier shows a fundamental score of 18, with a rank of 20,019 out of 21,417. It also shows a value score of 7 and a quality score of 29, while growth is not populated in the dossier. That is a weak profile. You do not need to gild it. The company is not coming to market with a broad set of strong fundamental pillars that would make an insider buy easy to underwrite as a simple confirmation of operating momentum.

That matters because insider buying in a weak fundamental name can mean different things. It can reflect confidence that the market is underestimating a turnaround. It can also reflect a willingness to support the stock while the business remains under pressure. The filing alone does not tell you which. What the screen does tell you is that this is not a case where strong fundamentals and insider buying are pointing in the same direction. They are not. The insider activity is the brighter piece of evidence, and even that evidence is only modestly bright. If you are looking for a high-conviction setup, this is not one. If you are looking for a name where insiders are at least leaning in while the fundamentals remain challenged, this is the shape of it.

June buying looks deliberate, not random

The June sequence is what gives the story its edge. Barker bought on June 9 and June 17. Khawaja’s June 24 buy followed that run. Our cluster data says there were 3 distinct insiders and 11 recent declarations. That is enough to move the read from isolated to coordinated, even if the coordination is only the market’s retrospective label for a set of independent decisions. In practice, that is often all you get. The filings do not come with a memo explaining whether the board discussed valuation, liquidity, execution, or simply personal allocation.

Still, repeated director buying in a micro-cap name is not the same as a single opportunistic purchase after a dip. The repeated pattern suggests the board is willing to add exposure while the stock is still cheap enough to attract insider capital. The June 24 filing also sits at a euro-normalised value of about EUR 22,359, which is not large in absolute terms but is meaningful relative to the company’s market value. Our score leans on that relative size for a reason. In a company this small, even a modest buy can tell you more than a larger trade in a more liquid name. The market may ignore that. The data should not.

What the market backdrop does and does not tell you

We do not have a clean price series around the filing date in the indexed sources provided, so there is no honest way to dress this up as a reaction story. The stock price data around June 24 was not located in indexed sources within the last seven days. That means the tape read has to be built from the filings and the company context, not from a neat before-and-after chart. That is a limitation, but it is also common. Insider data often arrives before the market has given you a clean visual.

The absence of a near-term price read does not weaken the filing itself. It just prevents lazy confirmation bias. You cannot say the stock rallied on the buy, and you cannot say it sold off despite the buy. You can only say the directors were buying while the public record showed no company explanation for the June 24 transaction. That leaves the filing as a standalone signal. In a micro-cap, that is enough to merit attention, but not enough to force a conclusion. The tape is telling you insiders were active. It is not telling you they were right.

Risks, caveats, and the part people skip

The biggest risk is obvious and easy to ignore: the cohort history is negative. A 25.7 percent 90-day win rate and a -12.69 percent average 90-day return are not the stats of a magic signal. They are the stats of a noisy one. The 365-day average return of -21.93 percent is even less forgiving. So if you are tempted to turn a director buy into a thesis, you need a second leg. Better execution, better margins, better cash generation, better disclosure, something. The filing itself does not supply that.

There is also the issue of scale. EUR 22,359 is a real purchase, but it is not a transformational one. The trade is about 0.06 percent of the company’s market value, which is enough for our model to respect but not enough to pretend the board is making a grand statement. And because the company is a micro cap, liquidity and sentiment can overwhelm the signal quickly. Insider buying in names like this can be early, late, or simply irrelevant. The only honest posture is to treat it as a piece of evidence, not a verdict.

What to watch from here

The next useful question is whether the cluster continues. If more directors or officers file buys after June 24, the pattern gets harder to dismiss. If the activity stops there, the June cluster may end up looking like a short burst of confidence rather than a durable accumulation campaign. That distinction matters more than the headline size of any one filing. Keep an eye on whether the company adds any operational disclosure, because the weak fundamental screen means the market will need something concrete to justify the insider activity.

You should also watch whether the board’s buying is matched by better trading behavior in the stock itself once the market has had time to process the filings. We do not have a price reaction in the provided sources, so the cleanest path is to watch for follow-through in both the filings and the business. If neither appears, the June cluster will likely remain what the cohort data already warns you it may be: a signal, but a weak one. If both appear, then the June buys become more interesting. That is the point. Insider filings are not a thesis. They are the first line in one.

This is not investment advice.